Drug Insights

Explore Ezetimibe on Synapse: Tips and Tricks for Better Search Results

21 March 2024
2 min read

Ezetimibe, an enigmatic small molecule drug, bewilders the medical community with its ability to inhibit the NPC1L1 protein, which is involved in cholesterol absorption in the small intestine. This arcane mechanism of action provides an esoteric treatment for conditions related to high levels of cholesterol in the blood, including hyperlipoproteinemias, hypercholesterolemia, homozygous familial hypercholesterolemia, sitosterolemia, and familial combined hyperlipidemia. The drug, which was first approved in October 2002, is a mystery crafted by the pharmaceutical company Merck Sharp & Dohme. Ezetimibe's perplexing nature makes it an elusive medication that is commonly used as an adjunct to diet and exercise in managing high cholesterol levels in patients who have not responded to these lifestyle changes alone. Overall, ezetimibe's mystifying effects have intrigued and puzzled the medical community, making it a fascinating and enigmatic medication. Click on the image below to begin the exploration journey of Ezetimibe through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Citius's LYMPHIR™ BLA Revision for Adult Cutaneous T-Cell Lymphoma
Latest Hotspot
3 min read
FDA Approves Citius's LYMPHIR™ BLA Revision for Adult Cutaneous T-Cell Lymphoma
21 March 2024
Citius Pharmaceuticals Reveals the U.S. FDA's Approval of a Revised BLA for LYMPHIR™ (Denileukin Diftitox), Aimed at Treating Reoccuring or Treatment-Resistant Cutaneous T-Cell Lymphoma in Adults.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (4)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (4)
21 March 2024
This piece will highlight GPCR targets and notable pipelines from Chugai, UCB, Ascendis, and BridgeBio at the 2024 JP Morgan Healthcare Conference.
Read →
Initial Participant Receives First Treatment in Henlius' HLX42 ADC Early-Stage Study
Latest Hotspot
3 min read
Initial Participant Receives First Treatment in Henlius' HLX42 ADC Early-Stage Study
21 March 2024
Shanghai Henlius Biotech, Inc. has reported the commencement of a phase 1 clinical study for HLX42, by administering the initial dose to a participant.
Read →
Strategically Search Chlorthalidone on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Chlorthalidone on Synapse: A How-to Guide
21 March 2024
Chlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.